157 related articles for article (PubMed ID: 35489010)
1. Real-world effectiveness of third- or later-line treatment in Japanese patients with HER2-positive, unresectable, recurrent or metastatic gastric cancer: a retrospective observational study.
Sakai D; Omori T; Fumita S; Fujita J; Kawabata R; Matsuyama J; Yasui H; Hirao M; Kawase T; Kishi K; Taniguchi Y; Miyazaki Y; Kawada J; Satake H; Miura T; Miyake A; Kurokawa Y; Yamasaki M; Yamada T; Satoh T; Eguchi H; Doki Y
Int J Clin Oncol; 2022 Jul; 27(7):1154-1163. PubMed ID: 35489010
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Irinotecan and Trifluridine/Tipiracil as Fourth-line Treatments After Third-line Nivolumab for Advanced Gastric Cancer.
Hayashi K; Furuta M; Furusawa K; Hamaguchi T; Watanabe M; Inokuchi Y; Onuma S; Hashimoto I; Suematsu H; Nagasawa S; Kanematsu K; Yamada T; Notsu A; Ogata T; Oshima T; Machida N; Furuse J; Maeda S
Anticancer Res; 2023 Jun; 43(6):2831-2840. PubMed ID: 37247885
[TBL] [Abstract][Full Text] [Related]
3. Randomised phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) versus trifluridine/tipiracil for previously treated patients with advanced gastric or esophagogastric junction adenocarcinoma (RETRIEVE study, WJOG15822G).
Takahashi N; Hara H; Nagashima K; Hirata K; Masuishi T; Matsumoto T; Kawakami H; Yamazaki K; Hironaka S; Boku N; Muro K
BMC Cancer; 2023 Aug; 23(1):726. PubMed ID: 37543568
[TBL] [Abstract][Full Text] [Related]
4. Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study.
Tabernero J; Shitara K; Zaanan A; Doi T; Lorenzen S; Van Cutsem E; Fornaro L; Catenacci DVT; Fougeray R; Moreno SR; Azcue P; Arkenau HT; Alsina M; Ilson DH
ESMO Open; 2021 Aug; 6(4):100200. PubMed ID: 34175675
[TBL] [Abstract][Full Text] [Related]
5. Protocol of a phase II study investigating the efficacy and safety of trifluridine/tipiracil plus ramucirumab as a third-line or later treatment for advanced gastric cancer.
Nakanishi K; Tanaka C; Kanda M; Miyata K; Machida N; Sakai M; Kobayashi D; Teramoto H; Ishiyama A; Sato B; Oshima T; Kajikawa M; Matsushita H; Ishigure K; Yamashita K; Fujitake S; Sueoka S; Asada T; Shimizu D; Sugita S; Kuwatsuka Y; Maeda O; Furune S; Murotani K; Ando Y; Ebata T; Kodera Y
Nagoya J Med Sci; 2024 Feb; 86(1):43-51. PubMed ID: 38505718
[TBL] [Abstract][Full Text] [Related]
6. Real-world safety and effectiveness of nivolumab in Japanese patients with unresectable advanced or recurrent gastric/gastroesophageal junction cancer that has progressed after chemotherapy: a postmarketing surveillance study.
Yamaguchi K; Boku N; Muro K; Yoshida K; Baba H; Tanaka S; Akamatsu A; Sano T
Gastric Cancer; 2022 Jan; 25(1):245-253. PubMed ID: 34581902
[TBL] [Abstract][Full Text] [Related]
7. Clinical Significance of Neutrophil-to-Lymphocyte Ratio/Serum Albumin Ratio in Patients With Metastatic Gastric or Gastroesophageal Junction Cancer Administered Trifluridine/Tipiracil.
Hashimoto I; Kano K; Onuma S; Suematsu H; Nagasawa S; Kanematsu K; Furusawa K; Hamaguchi T; Watanabe M; Hayashi K; Furuta M; Inokuchi Y; Machida N; Aoyama T; Yamada T; Rino Y; Ogata T; Oshima T
Anticancer Res; 2023 Apr; 43(4):1689-1697. PubMed ID: 36974783
[TBL] [Abstract][Full Text] [Related]
8. An exploration of trifluridine/tipiracil in combination with irinotecan in patients with pretreated advanced gastric cancer.
Mizukami T; Minashi K; Hara H; Nishina T; Amanuma Y; Takahashi N; Nakasya A; Takahashi M; Nakajima TE
Invest New Drugs; 2022 Jun; 40(3):614-621. PubMed ID: 35278170
[TBL] [Abstract][Full Text] [Related]
9. Trifluridine/Tipiracil in the Real-World Management of Metastatic Gastric and Gastroesophageal Junction Cancers in Canada.
Ding PQ; Dolley A; Cheung WY
Curr Oncol; 2022 Dec; 30(1):130-144. PubMed ID: 36661660
[TBL] [Abstract][Full Text] [Related]
10. Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer.
Satoh T; Kang YK; Chao Y; Ryu MH; Kato K; Cheol Chung H; Chen JS; Muro K; Ki Kang W; Yeh KH; Yoshikawa T; Oh SC; Bai LY; Tamura T; Lee KW; Hamamoto Y; Kim JG; Chin K; Oh DY; Minashi K; Cho JY; Tsuda M; Tanimoto M; Chen LT; Boku N
Gastric Cancer; 2020 Jan; 23(1):143-153. PubMed ID: 31087200
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the efficacy and safety of third-line treatments for advanced gastric cancer: A systematic review and network meta-analysis.
Zhang C; Xiang Y; Wang J; Yan D
Front Oncol; 2023; 13():1118820. PubMed ID: 36937403
[TBL] [Abstract][Full Text] [Related]
12. Real-World Data of Trifluridine/Tipiracil for Patients With Advanced Gastric Cancer: A Multi-Institutional Retrospective Study.
Matsumoto T; Yamamura S; Ikoma T; Kurioka Y; Doi K; Yasuda T; Boku S; Kawai T; Shibata N; Nagai H; Tsuduki T; Shimada T; Matsumoto Y; Tsumura T; Takatani M; Yasui H; Satake H
Clin Med Insights Oncol; 2022; 16():11795549221137135. PubMed ID: 36408335
[TBL] [Abstract][Full Text] [Related]
13. Real-world treatment sequencing and survival in previously treated advanced renal cell carcinoma patients receiving nivolumab monotherapy: a UK retrospective cohort study.
Waddell T; Fife K; Griffiths R; Sharma A; Dhokia P; Groves L; Hurst M; Tsang C; Sugrue D; McKenna S; Houghton J; Carroll R
BMC Cancer; 2022 Jun; 22(1):617. PubMed ID: 35668384
[TBL] [Abstract][Full Text] [Related]
14. High DCR and Better Survival in Patients with Advanced or Metastatic Gastric Cancer Receiving Anti-Angiogenic TKI plus Chemotherapy: A Real-World Study.
Nie C; Lv H; Chen B; Xu W; Wang J; Wang S; Liu Y; He Y; Zhao J; Chen X
Technol Cancer Res Treat; 2023; 22():15330338221150561. PubMed ID: 36632666
[No Abstract] [Full Text] [Related]
15. Real-world clinical outcomes of the combination of anti-PD-1 antibody, trastuzumab, and chemotherapy for HER2-positive gastric/gastroesophageal junction cancer.
Yang J; Shi Z; Zhang X; Liu Q; Cui X; Li L; Liu B; Wei J
Cancer Med; 2023 Apr; 12(8):9517-9526. PubMed ID: 36912199
[TBL] [Abstract][Full Text] [Related]
16. Sequential Treatment With Trifluridine/Tipiracil and Regorafenib in Refractory Metastatic Colorectal Cancer Patients: An AGEO Prospective "Real-World Study".
Coutzac C; Trouilloud I; Artru P; Henriques J; Masson T; Doat S; Bouché O; Coriat R; Saint A; Moulin V; Vernerey D; Gallois C; De La Fouchardière C; Tougeron D; Taieb J
Clin Colorectal Cancer; 2022 Jun; 21(2):132-140. PubMed ID: 35337742
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Prognostic Factors for Unresectable or Recurrent Gastric Cancer Treated with Nivolumab.
Ishido K; Tanabe S; Katada C; Ishibashi Y; Kitahara G; Onoue M; Kubota Y; Furue Y; Wada T; Watanabe A; Kusano C
J Gastrointest Cancer; 2023 Jun; 54(2):485-491. PubMed ID: 35437632
[TBL] [Abstract][Full Text] [Related]
18. Nivolumab versus irinotecan as third- or later-line treatment for advanced gastric cancer: a multi-center retrospective study.
Kumanishi R; Kadowaki S; Mitani S; Matsushima T; Ogata T; Narita Y; Masuishi T; Bando H; Tajika M; Yasui H; Hara H; Muro K
Int J Clin Oncol; 2023 Jun; 28(6):756-763. PubMed ID: 36943545
[TBL] [Abstract][Full Text] [Related]
19. Real-World Effectiveness of Nivolumab Monotherapy After Prior Systemic Therapy in Advanced Non-Small-Cell Lung Cancer in the United States.
Stenehjem DD; Lubinga SJ; Gupte-Singh K; Zhang Y; Le TK; Penrod JR; Smith CB
Clin Lung Cancer; 2021 Jan; 22(1):e35-e47. PubMed ID: 33187914
[TBL] [Abstract][Full Text] [Related]
20. Trifluridine/tipiracil plus bevacizumab as a first-line treatment for elderly patients with metastatic colorectal cancer (KSCC1602): A multicenter phase II trial.
Oki E; Makiyama A; Miyamoto Y; Kotaka M; Kawanaka H; Miwa K; Kabashima A; Noguchi T; Yuge K; Kashiwada T; Ando K; Shimokawa M; Saeki H; Akagi Y; Baba H; Maehara Y; Mori M
Cancer Med; 2021 Jan; 10(2):454-461. PubMed ID: 33249761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
